Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
Author: Parker, W.
Ho, M.
Scott, H.
Hughes, T.
Branford, S.
Citation: Blood, 2012; 119(10):2234-2238
Publisher: Amer Soc Hematology
Issue Date: 2012
ISSN: 0006-4971
Statement of
Wendy T. Parker, Musei Ho, Hamish S. Scott, Timothy P. Hughes and Susan Branford
Abstract: Specific imatinib-resistant BCR-ABL1 mutations (Y253H, E255K/V, T315I, F317L, and F359V/C) predict failure of second-line nilotinib or dasatinib therapy in patients with chronic myeloid leukemia; however, such therapy also fails in approximately 40% of patients in the chronic phase of this disease who do not have these resistant mutations. We investigated whether sensitive mutation analysis could identify other poor-risk subgroups. Analysis was performed by direct sequencing and sensitive mass spectrometry on 220 imatinib-resistant patients before they began nilotinib or dasatinib therapy. Patients with resistant mutations by either method (n = 45) were excluded because inferior response was known. Of the remaining 175 patients, 19% had multiple mutations by mass spectrometry versus 9% by sequencing. Compared with 0 or 1 mutation, the presence of multiple mutations was associated with lower rates of complete cytogenetic response (50% vs 21%, P = .003) and major molecular response (31% vs 6%, P = .005) and a higher rate of new resistant mutations (25% vs 56%, P = .0009). Sensitive mutation analysis identified a poor-risk subgroup (15.5% of all patients) with multiple mutations not identified by standard screening.
Keywords: Humans; Benzamides; Piperazines; Pyrimidines; Thiazoles; Fusion Proteins, bcr-abl; Protein Kinase Inhibitors; Sequence Analysis, DNA; DNA Mutational Analysis; Drug Resistance, Neoplasm; Mutation; Mass Spectrometry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Imatinib Mesylate; Dasatinib
Rights: Copyright © 2012 by American Society of Hematology
RMID: 0020117548
DOI: 10.1182/blood-2011-08-375535
Grant ID:
Appears in Collections:Molecular and Biomedical Science publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.